Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant + 5-Azacitidine in MDS
NCT01828346Phase 2Completed
- Sponsor
- TetraLogic Pharmaceuticals
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of birinapant in myelodysplastic syndrome (MDS), sponsored by TetraLogic Pharmaceuticals. Started Jun 2013; status: completed.
02
Drugs
birinapant
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01828346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01828346.